UNICA IRIS Institutional Research Information System

MORELLI, MICAELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 243.806
NA - Nord America 17.986
AS - Asia 5.844
SA - Sud America 1.087
AF - Africa 101
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 12
Totale 268.855
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 239.795
US - Stati Uniti d'America 17.805
CN - Cina 2.484
SG - Singapore 2.433
UA - Ucraina 1.484
BR - Brasile 915
SE - Svezia 829
DE - Germania 496
GB - Regno Unito 418
FI - Finlandia 374
VN - Vietnam 343
KR - Corea 170
FR - Francia 146
CA - Canada 113
IN - India 83
HK - Hong Kong 68
AR - Argentina 61
RU - Federazione Russa 53
MX - Messico 49
JP - Giappone 34
BD - Bangladesh 33
PL - Polonia 32
EC - Ecuador 31
ZA - Sudafrica 31
TR - Turchia 28
IQ - Iraq 27
NL - Olanda 27
BE - Belgio 26
CO - Colombia 26
ID - Indonesia 26
ES - Italia 25
AT - Austria 20
IL - Israele 19
EG - Egitto 17
EU - Europa 17
MA - Marocco 15
PK - Pakistan 14
CZ - Repubblica Ceca 13
CL - Cile 12
IE - Irlanda 12
KE - Kenya 10
LT - Lituania 10
PE - Perù 10
AU - Australia 9
PY - Paraguay 9
UZ - Uzbekistan 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
JM - Giamaica 8
RO - Romania 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
BO - Bolivia 7
NP - Nepal 7
TN - Tunisia 7
UY - Uruguay 7
IR - Iran 6
CH - Svizzera 5
DZ - Algeria 5
JO - Giordania 5
KZ - Kazakistan 5
MU - Mauritius 5
NO - Norvegia 5
PT - Portogallo 5
AL - Albania 4
ET - Etiopia 4
MY - Malesia 4
TH - Thailandia 4
TW - Taiwan 4
BY - Bielorussia 3
DK - Danimarca 3
HR - Croazia 3
NG - Nigeria 3
BG - Bulgaria 2
CR - Costa Rica 2
GE - Georgia 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GI - Gibilterra 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
ME - Montenegro 1
MN - Mongolia 1
Totale 268.845
Salva come PNG Salva come JPEG
Città #
Cagliari 233.108
Uta 5.888
Fairfield 2.329
Woodbridge 1.633
Ashburn 1.427
Chandler 1.273
Houston 1.100
Singapore 1.056
Seattle 945
Wilmington 917
Ann Arbor 849
Boardman 812
Jacksonville 796
Dallas 790
Cambridge 757
Nyköping 508
Beijing 462
Dearborn 316
Nanjing 271
Los Angeles 242
Hefei 222
New York 219
Boston 200
Santa Clara 169
Seoul 162
Shanghai 145
San Diego 131
Helsinki 130
Buffalo 127
Hangzhou 108
Ho Chi Minh City 100
The Dalles 90
Shenyang 89
Milan 88
Redwood City 78
Hebei 73
São Paulo 72
Dong Ket 70
Toronto 64
Nanchang 63
Hong Kong 62
London 61
Mountain View 58
Munich 58
Redondo Beach 57
Changsha 55
Guangzhou 55
Verona 50
Hanoi 49
Jiaxing 47
Chicago 45
Tianjin 44
Norwalk 43
Jinan 38
Rome 38
Council Bluffs 37
Zhengzhou 35
Washington 33
Brooklyn 31
Sassari 30
Auburn Hills 29
Rio de Janeiro 27
Orange 25
Tokyo 25
Ningbo 23
Brussels 22
Atlanta 20
Frankfurt am Main 20
Belo Horizonte 19
Brasília 19
Falls Church 19
Montreal 19
Phoenix 19
Warsaw 19
Chennai 18
Curitiba 18
Pune 17
San Jose 17
Da Nang 15
Indiana 15
Nuremberg 15
Oristano 15
Paris 15
Porto Alegre 15
Columbus 14
Mexico City 14
Stockholm 14
Kunming 13
Taizhou 13
Wuhan 13
Elk Grove Village 12
Johannesburg 12
Sestu 12
Dublin 11
Haiphong 11
Vienna 11
Denver 10
Guayaquil 10
Redmond 10
Salt Lake City 10
Totale 259.460
Salva come PNG Salva come JPEG
Nome #
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.296
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.262
Odor identification performance in idiopathic Parkinson’s disease is associated with gender and the genetic variability of the olfactory binding protein 3.630
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 3.595
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.519
Role of Adenosine in the basal Ganglia 3.325
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.077
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? 2.967
Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms 2.918
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.876
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.839
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.807
Modulation of rat 50-kHz ultrasonic vocalizations by glucocorticoid signaling: possible relevance to reward and motivation 2.788
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2.725
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.688
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.680
Methylxanthines and drug dependence: interactions and toxicity 2.665
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.654
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.631
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.610
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.597
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.502
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage 2.481
Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity 2.476
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2.472
Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls 2.465
Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age 2.433
Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50kHz Ultrasonic Vocalizations 2.405
Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation 2.381
Rhes counteracts dopamine neuron degeneration and neuroinflammation depending on gender and age 2.359
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 2.355
Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study 2.312
null 2.277
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists 2.276
Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease 2.275
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex 2.228
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.168
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.117
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.074
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.060
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2.057
NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease 1.980
Preface [ to The Adenosinergic System. A Non-Dopaminergic Target in Parkinson’s Disease] 1.960
Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: possible relevance to the motivational and dopamine-stimulating properties of the drug 1.944
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.929
Neurochemical and neurotoxic effects of MDMA (Ecstasy) and caffeine after chronic combined administration in mice 1.927
Metformin prevented dopaminergic neurotoxicity induced by 3,4-Methylenedioxymethamphetamine administration 1.886
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.845
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist 1.799
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.794
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson’s Disease 1.791
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease 1.774
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions 1.770
Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of Parkinson’s disease 1.769
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 1.762
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 1.757
Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques 1.702
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.668
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.605
Antiparkinsonian actions and interactions of adenosine antagonists 1.601
The small GTP-binding protein Rhes influences midbrain dopaminergic neurons: Behavioral and biochemical studies 1.544
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.529
Gender-dependent behavioral and biochemical differences in the A53T genetic mouse model of Parkinson’s disease 1.409
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.378
Adenosine signaling in the basal ganglia 1.275
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists 1.258
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.254
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.243
null 1.194
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 1.181
The 6-hydroxydopamine model of Parkinson's disease 1.166
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 1.139
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.139
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 1.134
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 1.126
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 1.111
null 1.108
Function of dopamine in the extrapyramidal and limbic systems 1.091
In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice 1.083
A2A receptor antagonism and dyskinesia in Parkinson’s Disease 1.072
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.072
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties 1.068
Caffeine Consumption and Changes in the Function of Dopaminergic Transmission: Evidence of a Hyperdopaminergic State in Rats Subchronically Treated with Caffeine 1.058
6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease 1.045
Adenosine A2A receptors and Parkinson's disease 1.038
null 1.012
Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse 1.005
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease 1.005
Anxyiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity 997
null 981
null 967
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 949
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 940
Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences 935
Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice 927
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 923
Effects of docosanyl ferulate, a constituent of Withania somnifera, on ethanol- and morphine-elicited conditioned place preference and ERK phosphorylation in the accumbens shell of CD1 mice 915
Birth asphyxia as the major complication in newborns: Moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care 913
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 903
Totale 189.323
Salva come PNG Salva come JPEG
Categoria #
all - tutte 369.976
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 369.976
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127.875 0 0 0 0 0 7.936 6.522 3.611 1.395 3.401 2.864 2.146
2021/202213.605 1.299 1.202 874 806 878 1.004 1.109 716 832 1.321 1.539 2.025
2022/202321.093 1.985 2.506 1.915 1.779 1.902 2.223 1.052 1.816 1.484 1.548 1.991 892
2023/202424.574 1.019 971 1.077 1.426 2.404 4.033 3.710 1.751 1.002 2.055 2.489 2.637
2024/202537.231 5.784 7.130 6.779 5.143 2.705 3.688 3.579 324 599 466 468 566
2025/20266.908 955 742 1.753 1.447 1.083 928 0 0 0 0 0 0
Totale 269.647